Close Menu

NEW YORK (GenomeWeb) – Castle Biosciences today announced it has secured a $6 million credit facility from Silicon Valley Bank.

The funding will be used to support commercial and clinical activities for the firm's cutaneous melanoma test called DecisionDx-Melanoma for determining the metastatic risk of patients with melanoma, Castle President and CEO Derek Maetzold said in a statement. The financing will also be used for general operations. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.